Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial

por Cortés, Javier, Rugo, Hope S., Awada, Ahmad, Twelves, Chris, Perez, Edith A., Im, Seock–Ah, Gómez-Pardo, Patricia, Schwartzberg, Lee S., Diéras, Veronique, Yardley, Denise A., Potter, David A., Mailliez, Audrey, Moreno-Aspitia, Alvaro, Ahn, Jin-Seok, Zhao, Carol, Hoch, Ute, Tagliaferri, Mary, Hannah, Alison L., O’Shaughnessy, Joyce
Publicado 2017

CX-072 (pacmilimab), a Probody(®) PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

por Naing, Aung, Thistlethwaite, Fiona, De Vries, Elisabeth G.E., Eskens, Ferry A.L.M., Uboha, Nataliya, Ott, Patrick A., LoRusso, Patricia, Garcia-Corbacho, Javier, Boni, Valentina, Bendell, Johanna, Autio, Karen A., Randhawa, Manreet, Durm, Greg, Gil-Martin, Marta, Stroh, Mark, Hannah, Alison L., Arkenau, Hendrik-Tobias, Spira, Alexander
Publicado 2021